Viral Reorganization of the Secretory Pathway Generates Distinct Organelles for RNA Replication

Nai-Yun Hsu,1,7 Olha Ilnytska,1,7 Georgiy Belov,2 Marianita Santiana,1 Ying-Han Chen,1 Peter M. Takvorian,1 Cyrilla Pau,1 Hilde van der Schaar,2 Neerja Kaushik-Basu,4 Tamás Balla,5 Craig E. Cameron,6 Ellie Ehrenfeld,2 Frank J.M. van Kuppeveld,3 and Nihal Altan-Bonnet1,*

1Department of Biological Sciences, Rutgers University, Newark, NJ 07102, USA
2Laboratory of Infectious Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892, USA
3Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, PO Box 9101 6500 HB Nijmegen, The Netherlands
4Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of Newark, Newark, NJ 07101, USA
5Section on Molecular Signal Transduction, NICHD, National Institutes of Health, Bethesda, MD 20892, USA
6Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College, PA 16803, USA
7These authors contributed equally to this work

*Correspondence: nabonnet@andromeda.rutgers.edu
DOI 10.1016/j.cell.2010.03.050

SUMMARY

Many RNA viruses remodel intracellular membranes to generate specialized sites for RNA replication. How membranes are remodeled and what properties make them conducive for replication are unknown. Here we show how RNA viruses can manipulate multiple components of the cellular secretory pathway to generate organelles specialized for replication that are distinct in protein and lipid composition from the host cell. Specific viral proteins modulate effector recruitment by Arf1 GTPase and its guanine nucleotide exchange factor GBF1, promoting preferential recruitment of phosphatidylinositol-4-kinase IIIb (PI4KIIIb) to membranes over coat proteins, yielding uncoated phosphatidylinositol-4-phosphate (PI4P) lipid-enriched organelles. The PI4P-rich lipid microenvironment is essential for both enteroviral and flaviviral RNA replication; PI4KIIIb inhibition interferes with this process; and enteroviral RNA polymerases specifically bind PI4P. These findings reveal how RNA viruses can selectively exploit specific elements of the host to form specialized organelles where cellular phosphoinositide lipids are key to regulating viral RNA replication.

INTRODUCTION

Viruses rely on their host for viability and replication. During infection, the virus and host become engaged in a dynamic duet, lasting from several hours to potentially years (in persistent infections), in which the virus initiates spatio-temporally ordered sequences of subcellular events, along the way dramatically altering cellular architecture and physiology. The host cell not only provides building blocks such as nucleotides and amino acids for viral metabolism but also can provide a structural platform for replication and viral assembly (Luetz et al., 2006). Many RNA viruses and even some DNA viruses such as the poxviruses rely on host intracellular membranes for replication (Miller and Krijnse-Locker, 2008; Salonen et al., 2005). In particular plus-strand RNA virus families, so called because upon infection their RNA can be directly translated into protein by host machinery, replicate and assemble on modified intracellular membranes (Miller and Krijnse-Locker, 2008; Salonen et al., 2005). The group of plus-strand RNA viruses includes many important human pathogens like picornaviruses (such as the enteroviral genus members poliovirus [PV] and Coxsackievirus B3 [CVB3], rhinovirus, and hepatitis A), coronaviruses (SARS), and flaviviruses (hepatitis C virus [HCV], Yellow Fever virus, Dengue Fever virus, West Nile virus).

Cells infected with plus-strand RNA viruses undergo a dramatic remodeling of their intracellular membranes, and RNA replication frequently takes place on the cytosolic leaflet of these remodeled membranes (Dales et al., 1965; Miller and Krijnse-Locker, 2008; Salonen et al., 2005). Replication membranes for picornaviruses, flaviviruses, and coronaviruses appear to originate from the endoplasmic reticulum (ER) (Schlegel et al., 1996), whereas for togaviruses and nodaviruses the endosomes/lysosomes and mitochondria are thought to be the membrane source (Maglino et al., 1998). Some viral replication enzymes have sequences that integrate into the host membrane bilayer, such as NS4B, a polytopic membrane protein of HCV (Lundin et al., 2003), and the 2B and 3A proteins of picornaviruses (Richards and Ehrenfeld, 1990). Many, however, are soluble proteins, whose mechanism of membrane association is unknown.

Plus-strand RNA viruses are critically dependent on intracellular membranes (Miller and Krijnse-Locker, 2008; Richards and Ehrenfeld, 1990; Salonen et al., 2005), but the properties...
of the replication membranes that are required to support viral RNA replication have not been defined. It has been speculated that membranes may limit diffusion of viral/host proteins and viral RNA, thereby increasing the local concentration of reaction elements; or that membranes may provide specific lipids that participate in the replication reactions themselves (Miller and Krijnse-Locker, 2008). A number of cellular factors have been implicated in viral RNA replication; e.g., several high-throughput siRNA screens have identified potential cellular factors whose knockdown reduces flavivirus replication (including components of the endosomal machinery, actin modulators, and phospholipid-modifying enzymes such as phosphatidylinositol-4-kinases), although the mechanism by which any of these proteins might regulate replication is not known (Berger et al., 2009; Borawska et al., 2009; Tai et al., 2009; Trotard et al., 2009; Vaillancourt et al., 2009). For PV and CVB3, both members of the enterovirus genus of the picornavirus family, we have shown that GBF1, a guanine nucleotide exchange factor (GEF) of the small Ras-family GTPase Arf1, was required for enteroviral RNA replication (Belov et al., 2007; Lanke et al., 2009). GBF1 catalyzes GDP/GTP exchange on Arf1, stabilizing membrane association, which in turn recruits various effectors to these membranes (Altan-Bonnet et al., 2004; Niu et al., 2005). In uninfected mammalian cells, GBF1 and Arf1 are both localized to the ER, ER-Golgi intermediate compartment (ERGIC), and the Golgi apparatus. Arf1’s known major effectors at these sites include coat proteins such as COPI complex and clathrin, which regulate membrane budding, and phosphatidylinositol-4-kinase III (PI4-KIII), which catalyzes the production of phosphatidylinositol-4-phosphate (PI4P) lipids at the membrane bilayer (Godi et al., 1999; Altan-Bonnet et al., 2004; Lee et al., 2004).

Here we focus on the in situ properties of the viral RNA replication membranes in cells infected with plus-strand RNA viruses. We demonstrate how remodeling of the host secretory pathway by enteroviral replication proteins generates organelles with unique protein and lipid composition geared for replicating viral RNA. We show that a specific enteroviral protein modulates effector recruitment by GBF1 and Arf1, promoting PI4KIII beta recruitment to secretory organelle membranes. This leads to disassembly of conventional secretory organelles and assembly of “replication organelles” that are juxtaposed to ER exit sites. PI4KIII beta at these organelle membranes produces a PI4P lipid microenvironment, which facilitates membrane binding of enteroviral RNA polymerase and viral RNA synthesis. Finally, we find that flaviviruses, specifically HCV, also induce and depend on the PI4P lipid microenvironments for RNA replication. Thus PI4KIII beta is a key cellular protein exploited by several plus-strand RNA viruses for replication.

RESULTS

We first investigated the in situ properties of RNA virus replication sites during enteroviral infections. Two hours after infection with CVB3, we were able to detect newly synthesized viral plus-strand RNA molecules (by fluorescence in situ hybridization) localized to the host secretory Golgi/trans-Golgi network (TGN) compartments by colabeling with Arf1-GFP (Figure 1A), a fluorescent protein-tagged version of the host small GTPase Arf1, which functionally mimics the native Arf1 GTPase in both uninfected and virally infected cells (Niu et al., 2005; Presley et al., 2002; Figure S1A available online). Viral replication protein 3A, a small tail-anchored membrane protein (Towner et al., 1996), and 3D pol, the RNA-dependent RNA polymerase (RdRp), both components of the viral replication enzyme complex (Richards and Ehrenfeld, 1990), were also localized to the Golgi apparatus and TGN compartments (Figure 1A), signifying that these compartments were sites of initial viral RNA synthesis.

By 4 hr post-infection, at the peak of enteroviral RNA replication, both viral RNA and viral replication enzyme levels rapidly increase. At this stage, Arf1 GTPase, viral RNA, 3D pol (Figure 1B, 4 hr p.i.), and other viral replication proteins (Figure S1B) were all redistributed to discrete cytoplasmic structures, which we term RNA replication organelles. These organelles persisted until the death of the cell, ~10 hr after start of infection, during which time both viral RNA and viral protein levels continued to increase at these structures (Figure 1B, 8 hr p.i.). Cellular GBF1, the GEF for Arf1, which we have previously shown to be required for enteroviral RNA replication, was colocalized with Arf1 (Figure 1C, Movie S1) and viral RNA and replication enzymes throughout infection (Figure 1D). The replication organelles at 4 hr post-infection were formed adjacent to ER exit sites as determined by antibody labeling of sec31, a component of COPII coats, which are recruited by activated Sar1 GTPases to the ER (Figure 1E). ER exit site number and distribution were largely unaffected throughout infection (not shown). Furthermore, reduction in levels of GBF1 (>70% depletion) and Arf1 (>50% depletion) proteins with siRNA (Figure 1F; Figures S2A–S2C) or transient expression of a dominant-negative, GTPase-inactive Sar1 protein [Sar1(T39N)] (Figure 1F), which is known to block the formation of ER exit sites (Kuge et al., 1994), inhibited by ~70% (for Arf1), ~80% (for GBF1), and ~50% (for Sar1T39N) the replication of enteroviral RNA molecules (Figures 1F and 1G), whereas none of these treatments alone had any effect on cell viability (Table S1). Thus secretory pathway machinery GBF1, Arf1, and Sar1 proteins were all required for or facilitated viral RNA replication. Note that in all siRNA treatment or transient plasmid expression experiments, viral RNA replicons, where the capsid protein-encoding sequences have been replaced by Renilla luciferase, were transfected into cells and assayed for bioluminescence as an indicator of viral RNA replication, thereby avoiding complications in the interpretation of data due to potential impact of any treatment on viral entry or virus assembly steps.

Atypical Replication Organelles Formed at ER Exit Sites for Viral RNA Replication

When we examined by high-resolution confocal imaging the replication membranes formed at 4 hr, we found that neither the coat proteins eCOPI (a component of the COPI coat complex) and clathrin nor the clathrin adaptor γ-adaptin, which are all known Arf1 effectors required for sorting/budding of cargo, including Golgi enzyme Galactosyltransferase (GalT), were colocalized with Arf1 at these organelles (Figures 2A–2C). Note that in uninfected cells Arf1 is colocalized at the Golgi/TGN/ERGIC with each of these components (Figures S3A–S3G). We assessed the colocalization between Arf1 and these

components, at the start (0 hr) and at 4 hr post-infection, by calculating the Pearson correlation coefficients (Figure S4). In infected cells COPI, clathrin, and γ-adaptin were dispersed across the cytoplasm while their total cellular levels remained unchanged as determined by western blotting (not shown). The lack of localization of these proteins to replication membranes

Figure 1. Enteroviral RNA and Replication Machinery Are Localized to the Host Secretory Pathway Organelles
(A) Viral RNA and viral replication protein (3A, 3Dpol) subcellular distribution in early stages of CVB3 RNA replication.
(B) Viral RNA and viral replication protein (3A, 3Dpol) subcellular distribution at peak stages of CVB3 RNA replication. See also Figure S1.
(C) Arf1-RFP and GBF1-YFP dynamics in CVB3-infected HeLa cell. Confocal time-lapse images of single cell are presented. See also Movie S1.
(D) GBF1 and viral RNA are colocalized in HeLa cells during CVB3 infection.
(E) Replication organelles, at peak replication, form adjacent to ER exit sites.
(F) Arf1 and GBF1 facilitate viral RNA replication. CVB3 replicon assays in HeLa cells pretreated with siRNA against Arf1 or GBF1. Bar graph presents maximum replication values for each condition, normalized to control samples transfected with nontargeting siRNA. Error bars are SEM from eight replicates for each condition (**p < 0.01). See also Figures S2A–S2C and Table S1.
(G) Functional ER exit sites facilitate viral RNA replication. PV replicon assays in HeLa cells transiently expressing Sar1[T39N] plasmid. Bar graph presents maximum replication values, normalized to control samples transfected with GFP. Error bars are SEM from eight replicates for each condition (**p < 0.01). See also Table S1. r.l.u% = relative light unit %. All fluorescence images were confocal images of optical slice thickness 1 μm. Scale bar, 10 μm.
was surprising given that Arf1 is able to bind and hydrolyze GTP at these sites (Belov et al., 2007) and hence a priori capable of recruiting these effectors. Consistent with the absence of coats, these organelles were not labeled with Golgi enzymes (Figure 2D; Movie S2), which typically sort into GBF1/Arf1-GTP/COPI membranes at the ERGIC and Golgi apparatus of uninfected cells (Figure S3C) (Lanoix et al., 1999). COPI-dependent membrane budding mediates anterograde transport from the ERGIC and hence is required for the maintenance of the Golgi apparatus (Lee et al., 2004). The absence of Golgi enzyme GalT localization to these organelles suggested a disruption of anterograde transport, and indeed at 4 hr post-infection the Golgi apparatus was completely disassembled (Movie S2); consistent with this, trafficking of secretory cargo to the cell surface was blocked (Figures S3H and S3I). In addition, ERGIC/Golgi matrix protein GM130 (Figure 2E) and endosomal components such as transferrin receptor (Figure S3J) were also absent from these membranes. Nevertheless, these organelles did contain a combination of other TGN, Golgi, and ERGIC components including TGN46, GGA1, Rab1b proteins as well as some ERGIC 53 (Figures 2F–2I; Figure S4). Recent studies have found that depletion of COPI proteins from cells can result in a loss of secretory pathway compartmentalization and the formation instead of membrane-bound structures that contain components of TGN, Golgi, and ERGIC proteins (Styers et al., 2008). Similarly, our findings here suggest that decoupling GFB1/Arf1 activity from COPI recruitment to membranes also results in a complete reorganization of the secretory pathway away from distinct separate conventional organelles.

**PI4KIIIβ Is a Component of Replication Organelles during Enteroviral Infection**

Phospholipid-modifying enzyme PI4KIIIβ, which catalyzes the production of PI4P lipids from PI (D’Angelo et al., 2008), is one of the critical downstream effectors of Arf1, recruited to and activated by Arf1 at the TGN and Golgi apparatus membranes and required for membrane trafficking (Balla and Balla, 2006; Godi et al., 1999). Given the absence of COPI or clathrin effectors at GFB1/Arf1-labeled replication organelles, we tracked the fate of PI4KIIIβ during enteroviral infection. Before infection, Arf1 and PI4KIIIβ were colocalized at the Golgi apparatus (Figure 3A, 0 hr), but at 4 hr post-infection, in striking contrast to COPI and clathrin, PI4KIIIβ remained colocalized with Arf1 (Figure 3A, 4 hr). This was confirmed by calculation of its Pearson coefficient, which showed no change between these two time points (Figure S4). This localization remained for the rest of the infection (Figure 3A, 6 hr) and was correlated with GFB1/Arf1 localization and activity, as Brefeldin A (BFA) treatment, which inactivates GFB1/Arf1 (by stabilizing the GFB1/Arf1-GDP complex) (Ni et al., 2005), dispersed Arf1 along with PI4KIIIβ (Figure 3B). Furthermore, PI4KIIIβ was not just spatiotemporally correlated with replication organelles but was in a physical association with the viral replication enzyme complex. Upon immunoprecipitation of PI4KIIIβ from infected cells at 4 hr post-infection, the enteroviral 3A, 3AB, 3CD, and 3Dpol proteins, which are all components of the replication complex, coprecipitated with it (Figure 3C). Importantly, TGN46, which was spatiotemporally localized with Arf1 (and hence PI4KIIIβ) (Figure 2F), was not coprecipitated, indicating the specificity of the complex between PI4KIIIβ and the viral replication proteins. In addition, immunoprecipitation with IgG alone did not precipitate PI4KIIIβ or any of the viral proteins (not shown).

**Enteroviral 3A Protein Can Selectively Recruit PI4KIIIβ to Membranes**

We next tested whether the CBV3 replication protein 3A could induce the selective recruitment of PI4KIIIβ to membranes observed during enteroviral infection. Membrane-anchored 3A proteins from CBV3 and PV have been documented to activate Arf1 by binding GFB1 and are required for viral RNA replication (Belov et al., 2007; Wessels et al., 2006; Lanke et al., 2009). At low levels of transient expression, 3A-myc was localized to the...
Golgi apparatus as determined by colocalization with Golgin97 (Figure 4A), along with native GBF1 and Arf1 proteins (Figures 4B and 4C). Although GBF1/Arf1 was present at these structures, the levels of βCOP, a component of the COPI coat complex, were decreased at these sites 2-fold compared to cells not expressing 3A-myc (Figure 4D, arrow; Figure 4G) whereas the total cellular βCOP levels were unchanged (data not shown). Significantly, despite a decrease in βCOP levels at 3A-labeled membranes, we found that PI4KIIIβ was redistributed with an ~3-fold increase to these membranes relative to cells where 3A was absent (Figure 4E, arrow; Figure 4G). In comparison, recruitment to the Golgi of structurally homologous enzyme PI4KIIIδ was unaffected by 3A-myc expression (Figures 4F and 4G). In cells expressing high levels of 3A-myc, the Golgi apparatus was disassembled and 3A was localized to discrete membranes juxtaposed to ER exit sites that were labeled with PI4KIIIβ but lacked βCOP and Golgi enzymes (Figures S5A–S5D)—a phenotype previously observed in CVB3-infected cells (Figure 2A, Figure 3A). Hence 3A expression alone enhanced the membrane recruitment of one Arf1 effector, PI4KIIIβ, over another, COPI, and caused disassembly of the Golgi apparatus, thus mimicking specific aspects of the virally infected phenotype.

PI4KIIIb Activity Regulates Viral RNA Synthesis

To determine whether PI4KIIIβ kinase activity was required for enteroviral RNA replication, we measured the effect of the small molecule PIK93, which selectively inhibits PI4KIIIβ (Knight et al., 2006), and found that enteroviral RNA replication was significantly reduced (Figures 5A–5C). RNA replication could be inhibited at concentrations as low as 125 nM and when PIK93 was added at time points after start of replication, indicating a requirement for PI4KIIIβ activity throughout the replication process; and PIK93, up to 2 μM, had little effect on cell viability (Figures S6A–S6C). When we reduced PI4KIIIβ levels with siRNA (Figures 5D–5F; Figure S2A) or transiently expressed a kinase-dead PI4KIIIβ (PI4KIIIβ-KD) (Toth et al., 2006) (Figures 5G–5I), both PV and CVB3 viral RNA replication were considerably delayed (Figures 5F and 5I) and accumulated reduced viral RNA levels compared to nontargeting siRNA or GFP-expressing control cells. PI4 kinase activity and PI4P lipids have been implicated in ER exit site maintenance (Blumental-Perry et al., 2006), but we found no change in distribution or number of ER exit sites in cells treated with PI4KIIIβ siRNA whereas cells treated with PI4KIIIβ siRNA had ~50% reduction (Figure S7). Hence downregulating PI4KIIIβ activity—a kinase critical for PI4P lipid synthesis—inhibited enteroviral RNA replication.

The inhibition of replication observed after reduction of PI4KIIIβ activity could be due to decreased viral RNA translation or proteolytic processing of the viral polyprotein into viral replication enzymes; alternatively inhibition could result from a direct effect on viral RNA synthesis. A block in any one or more of these stages would result in the inhibition of viral RNA replication observed (Figures 5A–5I). To distinguish among these we utilized a cell-free assay where viral RNA translation and processing can be uncoupled from viral RNA synthesis (Barton and Flanagan, 1993; Fogg et al., 2003). We found that inhibition of PI4KIIIβ kinase activity had no impact on viral RNA translation or its subsequent proteolytic processing of the polytopic protein into the individual viral replication proteins (Figure 5J). There was, however, a >70% inhibition of viral RNA synthesis (Figure 5K). Thus viral RNA synthesis is regulated by PI4KIIIβ activity.

PI4P Lipid Microenvironment at Replication Organelles Regulates Enteroviral RNA Replication

Given the localization of PI4KIIIβ to replication organelles, and the inhibition of replication after knockdown of PI4KIIIβ activity, we monitored the levels of cellular PI4P, a known lipid product of PI4KIIIβ activity, during infection with CVB3. PI4P levels increased ~5-fold within the first 4 hr of CVB3 infection (Figure 6A). Notably levels of PI4P, which can be derived from PI4P lipids, were not changed and even decreased during this
time (data not shown). To test if PI4P lipids themselves, independent of PI4KIIIβ, regulated viral RNA replication, we ectopically expressed in cells Sac1 phosphatase, which specifically converts PI4P lipids back to PI (Blagoveshchenskaya et al., 2008). The inhibition was only ~40% (Figure 6B) likely due to continued production of PI4P by endogenous PI4 kinase activity, or because not all cells that were transfected with enterovirus RNA were transiently expressing the Sac1 phosphatase.

We next determined if the PI4P lipids were localized to replication membranes. We utilized GFP-tagged FAPP1-PH proteins, which are known to bind PI4P lipid-containing membranes in the presence of Arf1 (Godi et al., 2004; Toth et al., 2006). We coexpressed Arf1-RFP and FAPP1-PH-GFP and acquired time-lapse confocal images of individual cells during infection with CVB3 to monitor the distribution of both Arf1 and PI4P lipids (Figure 6C; Movie S3). At the start of infection the major PI4P pool in the cell was found at the Golgi/TGN compartment. By 4 hr post-infection, all the newly formed Arf1-labeled organelles contained PI4P lipids (Figure 6C, 4 hr). The PI4P labeling was independently confirmed by staining with antibodies to PI4P lipids (data not shown).

**PI4KIIIβ Activity Responsible for PI4P Lipid Microenvironment at Replication Organelles**

By acutely treating cells coexpressing FAPP1-PH-GFP and Arf1-RFP with PIK93 inhibitor at 4 hr post-infection, we demonstrated that the PI4P lipids at replication organelles were the products of PI4KIIIβ activity. Using time-lapse imaging, we followed the fate of FAPP1-PH-GFP and Arf1-RFP within individual cells pre- and post-PIK93 treatment. We found that within ~30 min of PIK93 addition, ~60% of the FAPP1-PH-GFP associated with replication organelles was lost whereas the Arf1-RFP pattern was largely unaffected (Figures 6D and 6E). This demonstrated that a significant fraction of the PI4P lipids at replication sites were a product of PI4KIIIβ activity and that Arf1 binding to membranes was not dependent on PI4P lipids. Furthermore it indicated that the PI4P lipid microenvironment at these membranes was not static but turning over, as in the absence of PI4 kinase activity, the lipids were quickly lost from these sites. This could be due to conversion back to PI, potentially as a result of endogenous Sac1 phosphatase activity or transport out of replication membranes. The lack of complete FAPP1-PH-GFP dispersal upon PIK93 treatment also suggested that other PI4 kinase family members might be harnessed for PI4P lipid synthesis as well during infection at these sites.

**RNA Polymerase 3Dpol Binds PI4P Lipids**

Enteroviral RNA is synthesized by viral replication complex enzymes, which include the RdRp 3Dpol. The mechanism by
which the soluble 3D<sup>pol</sup> protein associates with membranes and catalyzes the synthesis of viral RNA on these membranes is unknown. Given the in vivo localization of the viral replication complex proteins including 3D<sup>pol</sup> to membranes enriched in PI4P lipids (Figures 1A and 1B, Figure 6C), we tested whether the 3D<sup>pol</sup> protein had any affinity for PI4P lipids. We assayed for binding of 3D<sup>pol</sup> with PI4P lipids over all other phosphatidylinositides and phospholipids (Figures 6F and 6G). Thus 3D<sup>pol</sup> alone, independent of any of the other components of the viral replication complex, has a high and specific affinity for PI4P lipids that potentially can regulate both its binding to cellular membranes and its subsequent RNA synthesis activities.

PI4P Lipid Microenvironment Regulates HCV RNA Replication

Given that the PI4P lipid microenvironment was required for enteroviral RNA replication, we next tested if any other plus-strand RNA virus was similarly dependent. HCV, an enveloped virus that is a member of the flaviviruses, assembles its replication enzymes and replicates its RNA on remodeled ER membranes (Wo¨ lk et al., 2008). We coimmunostained the Huh7-derived liver cell line 3-5B(HCV), which contains autonomously replicating, subgenomic, dicistronic, selectable HCV RNAs from the infectious HCV-N1b strain as well as expressing HCV nonstructural proteins (Ikeda et al., 2002), with antibodies against PI4P lipids and the HCV protein NS5A. NS5A, a membrane-associated protein that is part of the HCV replication complex of enzymes and is colocalized with HCV RNA molecules (Wo¨ lk et al., 2008), allowed us to identify the cellular viral}

**Figure 5. PI4KIII<sub>b</sub> Activity Is Required for Enteroviral RNA Replication**

(A and B) PIK93 block of PI4KIII<sub>b</sub> activity inhibits CVB3 and PV RNA replication. CVB3 and PV replicon assays in cells treated with 500 nM and 1 μM PIK93 are shown. Bar graphs present maximum replication values for CVB3 (A) and PV (B) with PIK93 treatment, normalized to control (DMSO) treatment. See also Figures S6A–S6C.

(C) Kinetics of inhibition by PIK93 presented for the CVB3 replicon.

(D and E) Reduction of PI4KIII<sub>b</sub> levels with siRNA inhibits CVB3 and PV RNA replication. CVB3 and PV replicon assays in HeLa cells; bar graphs present maximum replication values for each condition, normalized to control (nontargeting) siRNA. See also Figure S2A.

(F) Kinetics of inhibition by PI4KIII<sub>b</sub> siRNA presented for PV replicon.

(G and H) Expression of ectopic kinase-dead PI4KIII<sub>b</sub> (PI4KIII<sub>b</sub>-KD) inhibits CVB3 and PV replication. CVB3 and PV replicon assays in HeLa cells; bar graphs present maximum replication values for each condition, normalized to control (GFP) plasmid ectopic expression.

(I) Kinetics of inhibition by PI4KIII<sub>b</sub>-KD presented for the CVB3 replicon. Error bars in each CVB3 assay are SEM of six CVB3 samples and each PV assay is SEM for eight PV samples. (*p < 0.01).

(J and K) PI4KIII<sub>b</sub> activity regulates viral RNA synthesis. Cell-free PV RNA translation (J) and synthesis (K) assays performed in the presence of PIK93.
Figure 6. PI4P Lipid Microenvironment within Replication Organelles Regulates both Enteroviral and Flaviviral RNA Replication

(A) Cellular PI4P lipid levels rise in CVB3 infection. Total cellular PI4P lipids were quantified over time. Error bars are SEM from duplicate samples (**p < 0.01).

(B) Reduction in PI4P lipid levels inhibits enteroviral RNA replication. PV replicon assays in HeLa cells ectopically expressing Sac1 are shown. Inset: western blot showing increase in Sac1 levels after 16 hr of ectopic expression. Bar graph presents maximum replication values, normalized to control (GFP) plasmid ectopic expression. Error bars are SEM from eight replicates cells (**p < 0.01).

(C) PI4P lipids localize to enteroviral replication organelles. Time-lapse confocal images of single HeLa cell infected with CVB3, coexpressing FAPP1PH-GFP/Arf1-RFP (see also Movie S3).

(D) PI4KIII activity is responsible for PI4P lipids at enteroviral replication organelles. Time-lapse confocal image of single HeLa cell coexpressing FAPP1-PH-GFP/ARF1-RFP pre- and post-PIK93 treatment at 4 hr post-infection with CVB3.

(E) Quantification of FAPP1PH-GFP to Arf1-RFP fluorescence from (D) expressed as a ratio. Error bars are SEM from ten cells for each condition.

(F and G) PV RNA polymerase specifically and preferentially binds PI4P lipids. Purified recombinant 3Dpol enzyme was incubated with membrane strips that were previously spotted with different lipids. Antibodies detected 3Dpol binding. Two representative blots are shown. Binding was quantified and plotted in bar graph as a ratio over background non-lipid spotted membrane from three different experiments for each lipid type.
RNA replication sites. First by quantification of PI4P-associated antibody fluorescence we found that 3–5B(HCV) cells, compared to parental Huh7, had an ~45% increase in the total cellular levels of PI4P (Figure 6H). Second, whereas in the parental Huh7 cells the PI4P lipid pool was localized to the perinuclear Golgi apparatus/TGN region, in 3–5B(HCV) cells the abundant PI4P lipids were found colocalized with NS5A at discrete punctate sites all across the cytoplasm (Figure 6I, inset). Notably PI4KIIÎ± reduction by siRNA knockdown (~90% by immunofluorescence staining, not shown) had greater effect on lowering PI4P levels within 3–5B(HCV) cells compared to PI4KIIÎ± reduction, though it is likely that both enzymes contribute to the increased cellular PI4P levels (Figures 6J and 6K). Finally, to test whether PI4P lipids were also required for HCV RNA replication, we measured the replication of HCV J6/JFH (p7-Rluc2A) replicons (Jones et al., 2007) in Huh7 cells where we had depleted the PI4P lipid pool by transiently expressing the Sac1 phosphatase either alone or in combination with catalytically inactive PI4KIIÎ±-KD. HCV RNA replication was inhibited by >50% when Sac1 was expressed alone, and the effect was greater (~70%) in the presence of PI4KIIÎ±-KD, as would be predicted (Figure 6L, Sac+PI4KIIÎ±KD). Thus the PI4P lipid microenvironment in the membrane is an important regulator of both entero viral and flaviviral RNA replication.

**DISCUSSION**

Here we demonstrate that both enteroviruses and flaviviruses exploit host PI4KIIÎ± enzymes and replicate their respective viral RNA on PI4P lipid-enriched membranes. Furthermore we show that the enteroviral membrane protein 3A can reorganize the host secretory trafficking pathway to enhance the recruitment of PI4KIIÎ± to host membranes in order to generate a PI4P lipid-enriched membrane microenvironment to which the soluble viral RdRp 3Dpol can bind.

Based on our findings we propose a model for the reorganization of the secretory pathway in enteroviral infections, which generates PI4P lipid-enriched replication organelles (Figure 7). Here membrane-bound enteroviral 3A proteins bind and modulate host GBF1/Arf1 to enhance recruitment of PI4KIIÎ± to membranes, over COPI and other coat proteins, where it will catalyze the production of PI4P lipids, leading to the biogenesis of a PI4P lipid-enriched membrane microenvironment that is distinct from that in uninfected cells. This PI4P lipid-rich microenvironment will in turn promote the recruitment and stabilization on the membrane of the RdRp 3Dpol from the cytosolic pool. 3Dpol as part of a replication complex of 3A and several other viral proteins will then initiate RNA synthesis at these membranes (Figure 7A).

Enteroviral RNA replication begins on existing PI4P lipid-containing organelles including the Golgi and TGN, which have the highest steady-state levels of this lipid in uninfected cells (Godi et al., 1999) (Figure 7B, uninfected). Viral RNA replication is a positive feedback loop, where newly synthesized viral RNA molecules are translated into increasing amounts of viral replication proteins including 3A, which then further replicate viral RNA. Since 3A modulates GFBF1/Arf1 effector recruitment, its impact on GFBF1/Arf1/coat/PI4KIIÎ± interactions will become inescapable as its levels rise. The selective recruitment of PI4KIIÎ± to membranes over COPI will eventually disrupt secretory membrane trafficking and lead to Golgi disassembly by decreasing anterograde transport from the ERGIC and intra-Golgi trafficking, both COPI-dependent processes (Lee et al., 2004) (Figure 7B, 2 hr). Furthermore 3A-bound membranes emerging de novo from ER exit sites will develop into PI4P lipid-enriched uncoated membranes (Figure 7B, 4 hr). In addition to forming replication organelles, disruption of secretory pathway integrity has been implicated in the suppression of cytokine secretion and MHC-dependent antigen presentation (Deitz et al., 2000), thus serving multiple functions for efficient enterovirus replication and propagation.

Newly formed replication organelles have an atypical combination of host protein and lipids, including being enriched in PI4P lipids and containing PI4KIIÎ±, TGN46, GGA1, Rab1b, and ERGIC53, which in uninfected cells would be segregated among different secretory compartments. Modulation of host secretory machinery by viral proteins and its consequences are highly complex. The localization of some components can be explained through affinity for either PI4P lipids (e.g., GGA1) or GBF1 (e.g., GGA1, Rab1b) (Monetta et al., 2007; Wang et al., 2007). However GGA1 can bind clathrin and γ-adaptin (Bonifacino, 2004; Lefrancó and McCormick, 2007) and GBF1 can bind COPI (Deng et al., 2009), but neither COPI, clathrin, nor γ-adaptin are present at replication sites. Potentially the high PI4P lipid microenvironment in conjunction with viral proteins may modulate interactions among GBF1, Arf1, and specific effectors, promoting the sorting/partitioning of some components while deterring others.

Arf1 recruits a variety of effectors to membranes, yet little is known on the mechanism of the selection process. ArfGEFs not only facilitate Arf recruitment and activation but also regulate effector selection: e.g., GBF1 can bind COPI and GGA proteins. Which ArfGEF recruits PI4KIIÎ± is not known in uninfected cells, but GBF1 in the context of 3A proteins may facilitate the

---

**a)** Cellular PI4P lipid levels rise in HCV replicating cells. Quantification of PI4P with anti-PI4P primary antibodies of 3–5B(HCV) cells, normalized as % of PI4P lipid quantification within Huh7 cells. Error bars are SEM from ten cells for each cell type.

**b)** PI4P lipids localize to HCV replication membranes. PI4P lipid and NS5A protein distribution in Huh7 and 3–5B(HCV) cells were determined by immunostaining with anti-PI4P and anti-NS5A antibodies.

**c)** Reduction of PI4P lipids inhibits HCV replication. HCV replication assays conducted with J6/JFH (p7-Rluc2A) replicons in Huh7 cells ectopically expressing Sac1, PI4KIIÎ±-KD, or both plasmids are shown. Bar graph presents maximum replication value normalized to control (GFP) plasmid ectopic expression. Error bars are SEM from eight replicates of cells for each treatment condition (⁎p < 0.01). All fluorescence images were confocal images of optical slice thickness ~1 μm. Scale bar, 10 μm.
PI4P lipid-enriched membranes and PI4KIII\textsuperscript{b} (Figures 6H–6L). Whereas most enteroviral infections disrupt enzymes (Dubuisson et al., 2002), nevertheless depends on are sequence- and structure-wise distinct from enteroviral during infection.

Indeed secretory trafficking is attenuated in HCV-infected cells kinetics of secretory trafficking and budding/export of HCV. 

Rising levels of 3A combined with its modulation of effector recruitment by GBF1/Arf1 will enhance the recruitment of PI4KIII\textsuperscript{b} over COPI, leading to a decreased rate of anterograde transport out of the ERGIC and subsequent disassembly of the Golgi/TGN organelles. 4 hr: Enhanced recruitment of PI4KIII\textsuperscript{b} over COPI results in the formation of uncoated PI4P lipid-enriched organelles adjacent to ER exit sites. The PI4P lipid-enriched microenvironment of these organelles facilitates the ongoing assembly of newly synthesized viral replication proteins such as RdRp 3D\textsuperscript{pol} and viral RNA replication.

recruitment of PI4KIII\textsuperscript{b} in infected cells, given that PI4KIII\textsuperscript{b} is colocalized with GBF1 and communoprecipitated with 3A (Figures 3A and 3C), where the latter is known to bind GBF1 (Wessels et al., 2006). It also remains to be explored whether GBF1, Arf1, or any other viral or host proteins may be stimulating PI4KIII\textsuperscript{b} activity to reach the high PI4P lipid levels observed during infection.

HCV, an enveloped flavivirus whose replication enzymes are sequence- and structure-wise distinct from enteroviral enzymes (Dubuisson et al., 2002), nevertheless depends on PI4P lipid-enriched membranes and PI4KIII\textsuperscript{b} for replication (Figures 6H–6L). Whereas most enteroviral infections disrupt secretory trafficking, flaviviruses utilize the secretory pathway to mature into virions and exit the cell (Mackenzie and Westaway, 2007). HCV RNA is replicated on remodeled ER membranes whereas structural proteins are located to lipid droplets (Miyanari et al., 2007). Through a complex assembly process not yet understood virions bud out of the ER and are released from the cell through exocytosis. The presence of high levels of PI4P lipids at ER membranes, in addition to regulating HCV RNA replication, could impact the organization and kinetics of secretory trafficking and budding/export of HCV. Indeed secretory trafficking is attenuated in HCV-infected cells (Konan et al., 2003).

In mammalian cells, PI4P lipids, the most abundant monophosphorylated inositol phospholipids, were previously viewed only as PIP2 precursors (D’Angelo et al., 2008). However independent functions have recently emerged: several host proteins including CERT, OSBP, and FAPP1/2 specifically bind PI4P lipids (Lemmon, 2008); and PI4P lipids regulate selective autophagy and ER exit site biogenesis (Blumental-Perry et al., 2006; Yamashita et al., 2006). PI4P lipids can locally change membrane curvature (Ishiyama et al., 2002; McMahon and Gallop, 2005). PI4P lipid-enriched membranes during viral infection may generate high-curvature membrane pockets to shield viral components from host defense. Little is known about how soluble viral RNA polymerases are recruited to membranes. PI4P lipids may provide docking sites to concentrate viral proteins for efficient RNA synthesis. Enteroviral RdRp 3D\textsuperscript{pol} preferentially binds PI4P lipids over all other cellular lipid components, and PI4P depletion specifically perturbs viral RNA synthesis (Figure 5 and Figure 6). This raises the possibility that enteroviruses rewire host secretory machinery to generate PI4P lipid-enriched membranes to recruit to and concentrate on membrane RNA polymerases. Furthermore, PI4P lipid binding may also induce conformational changes and modulate RdRp enzymatic activity. The phosphoinositide-binding domain on 3D\textsuperscript{pol} is unknown and studies to identify the lipid-binding site and investigate its occurrence across different RdRps are underway.

In summary, we show that the PI4P lipid microenvironment is an important facilitator of plus-strand viral RNA replication. Enteroviruses reorganize the cellular secretory trafficking machinery away from building conventional secretory organelles to generate organelles whose membranes are enriched in PI4P lipids.
lipids. Cellular PI4 kinases are key players in this process. The findings with both picornavirus and flavivirus family members highlight the importance of PI4P lipids and PI4 kinases for viral RNA replication and will instigate studies to determine how widespread this dependence on PI4P lipids is among RNA viruses and the mechanism by which these lipids modulate viral RNA synthesis machinery. Furthermore small molecules targeting PI4 kinases, such as PIK93, may provide a basis for the design of new classes of therapeutics against viral RNA replication.

**EXPERIMENTAL PROCEDURES**

**Live-Cell Imaging**

All imaging was performed on a Zeiss LSM510 META confocal laser scanning confocal microscope (Carl Zeiss, USA) using high-magnification, high numerical aperture objectives. Live cells were maintained on the microscope stage in a temperature, CO₂, and humidity-controlled environmental chamber. Time-lapse images were acquired every 5 min for the duration of infection.

**Immunofluorescence and Analysis**

Cells were plated on coverslips, fixed with 4% formaldehyde PBS solution, permeabilized with 0.2% saponin, incubated with primary, and fluorophore-tagged secondary antibodies, and mounted. Confocal images were obtained and analyzed with Zeiss LSM or Image J software.

**Fluorescence in Situ Hybridization**

Alexa555-labeled CVB3 plus-strand RNA-specific probes were synthesized using FISH Tag RNA kit (Invitrogen Corp., CA). For colocalization of CVB3 plus-strand RNA with Arf1 or GBF1, infected cells were fixed with 4% formaldehyde followed by overnight permeabilization with 70% ethanol. Cells were rehydrated in SSC buffer and hybridized with RNA probes overnight in hybridization buffer. GBF1 or Arf1 was immunostained with primary and Alexa488-labeled secondary antibodies in the absence of detergents.

**PI4P Lipid Extraction and Quantification**

Cells were harvested, PI4P extracted, spotted on nitrocellulose membrane strips, and detected by FAPP1 protein-derived PI4P detectors followed by secondary and tertiary antibodies as described in Dowier et al. (2002).

**siRNA Transfection**

Cells were seeded in 96-well plates (for the replicon assay) or 12-well plates for siRNA transfection. Typically 50 nM of each siRNA was transfected via DharmaFECT1 (Dharmacon, CO) and incubated for 48 hr.

**Replicon Assays**

pRib-Rluc (CVB3), pXpA-RenR(PV), and J6/JFH (p7-Rluc2A) (HCV) plasmids were in vitro-transcribed with pRib-Rluc (CVB3), pXpA-RenR(PV), and J6/JFH (p7-Rluc2A) (HCV) plasmids utilized to measure viral RNA replication. Plasmids were in vitro-transcribed with Redivue [³⁵S] methionine (Amersham GE, NJ), incubated, and then resolved by SDS-PAGE for visualization of translation products. Total membrane pellets from translation reactions were suspended in GuHCl free-medium containing cyclohexamide and P72-CTP and replication reactions were performed in the absence of any protein synthesis. Replicated PV RNA was resolved on agarose gels, which were then exposed to film for detection and quantification of PV RNA. PIK93 dissolved in DMSO was added to a final concentration of 0.4 mM or 2 mM in both the translation and replication assay stages; control reaction mixtures contained DMSO only.

**Cell-free Translation and Replication Assays**

HeLa S10 extracts for translation-replication reactions were prepared and utilized for in vitro RNA translation and replication reactions as described (Barton and Flanagan, 1993; Fogg et al., 2003). Translation reaction mixtures included in vitro-synthesized PV RNA transcripts in the presence of 2 mM GuHCl to block replication. An aliquot from each translation reaction mixture was mixed with Redivue [³⁵S] methionine (Amersham GE, NJ), incubated, and then resolved by SDS-PAGE for visualization of translation products. Total membrane pellets from translation reactions were suspended in GuHCl free-medium containing cyclohexamide and P72-CTP and replication reactions were performed in the absence of any protein synthesis. Replicated PV RNA was resolved on agarose gels, which were then exposed to film for detection and quantification of PV RNA. PIK93 dissolved in DMSO was added to a final concentration of 0.4 mM or 2 mM in both the translation and replication assay stages; control reaction mixtures contained DMSO only.

**Statistical Analysis**

Data were expressed and plotted as means ± standard error of the mean (SEM). Unpaired Student’s t tests were used to compare the mean of control and experimental groups. The actual p value and sample size of each experimental group were provided in the respective figure legends.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Extended Experimental Procedures, seven figures, one table, and three movies and can be found with this article online at doi:10.1016/j.cell.2010.03.050.

**ACKNOWLEDGMENTS**

We thank J. Lippincott-Schwartz, S.M. Simon, K. Hirschberg, T. Ward, R. Hegde, R. Collins, J. Arnold, and G. Altan-Bonnet for insightful discussions. E.E. and G.B. were supported by the Intramural Research Program of the NIH (NIAID); T.B. was supported by the Intramural Research Program of the NIH(NICHD); C.E.C. was supported by grant AI035351 (NIAID,NIH); F.J.M.v.K was supported by Netherlands Organisation for Scientific Research (NWO-VIDI-917.46.306, NWO-ECHO-700.57.001); N.K.B. was supported by grant DK08687 (NIDDK,NIH); and N.A.-B. was supported with grant MCB0822058 from the National Science Foundation and grant 649117 from the Busch Foundation.

Received: September 28, 2009
Revised: January 12, 2010
Accepted: March 18, 2010
Published: May 27, 2010

**REFERENCES**


**Cell** 141, 799–811, May 28, 2010 ©2010 Elsevier Inc. 809
A COPI coat subunit interacts directly with an early-Golgi localized Arf


sites regulates ER export. Dev. Cell


sites regulates ER export. Dev. Cell 11, 671–682.


Dynamics of GBF1, a Brefeldin A-sensitive Arf1 exchange factor at the Golgi. J. Biol. Chem.


